Date: 2013-12-11
Type of information: Licensing agreement
Compound: therapeutic antibodies targeting an immune checkpoint molecule such as ICOS (Inducible T-cell COStimulator)
Company: GSK (UK) Inserm Transfert (France)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease:
Details: * On December 11, 2013, Inserm Transfert and GSK have signed an exclusive worldwide license agreement to develop therapeutic antibodies targeting an immune checkpoint molecule for the emerging area of immuno-oncology. The deal is based upon Inserm research developed by Professor Daniel Olive and his team at CRCM-Institut Paoli-Calmettes (IPC) that aims to investigate the function of immune-checkpoint molecules such as ICOS (Inducible T-cell COStimulator). This protein along with other co-stimulatory proteins plays an important role in immune responses and could be a potential major target for both cancer and other therapeutic strategies.
Under the terms of the agreement, Inserm Transfert has granted GSK exclusive worldwide rights to develop and commercialise the monoclonal antibodies, which modulate ICOS on the surface of T cells and enhances anti-tumour immune responses.
Financial terms: In addition to an undisclosed upfront fee, Inserm Transfert will receive milestones from GSK linked to the development of the product(s), as well as royalties on sales from any product that is successfully commercialised from the collaboration
Latest news:
